[go: up one dir, main page]

ES2072096T3 - 4-fenilpiperidinas n-sustituidas antagonistas de opioides. - Google Patents

4-fenilpiperidinas n-sustituidas antagonistas de opioides.

Info

Publication number
ES2072096T3
ES2072096T3 ES92302729T ES92302729T ES2072096T3 ES 2072096 T3 ES2072096 T3 ES 2072096T3 ES 92302729 T ES92302729 T ES 92302729T ES 92302729 T ES92302729 T ES 92302729T ES 2072096 T3 ES2072096 T3 ES 2072096T3
Authority
ES
Spain
Prior art keywords
substituted
opioid antagonists
phenylpiperidines
antagonists
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92302729T
Other languages
English (en)
Inventor
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2072096T3 publication Critical patent/ES2072096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ANTAGONISTAS OPIOIDES DE LA 4-FENIL-PIPERIDINA-N-SUBSTITUIDA. SE SUMINISTRAN PIPERIDINAS N-ALILAMINO-3, 4, 4-SUBSTITUIDAS QUE SON UTILES COMO ANTAGONISTAS OPIOIDES PERIFERICOS.
ES92302729T 1991-03-29 1992-03-27 4-fenilpiperidinas n-sustituidas antagonistas de opioides. Expired - Lifetime ES2072096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/677,708 US5159081A (en) 1991-03-29 1991-03-29 Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists

Publications (1)

Publication Number Publication Date
ES2072096T3 true ES2072096T3 (es) 1995-07-01

Family

ID=24719813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92302729T Expired - Lifetime ES2072096T3 (es) 1991-03-29 1992-03-27 4-fenilpiperidinas n-sustituidas antagonistas de opioides.

Country Status (6)

Country Link
US (1) US5159081A (es)
EP (1) EP0506468B1 (es)
JP (1) JP3059292B2 (es)
CA (1) CA2064382C (es)
DE (1) DE69202186T2 (es)
ES (1) ES2072096T3 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5681830A (en) * 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
CA2110095A1 (en) * 1992-12-08 1994-06-09 Teruo Komoto Arylamide derivatives
CA2168432C (en) * 1993-07-30 2004-03-23 Kwen-Jen Chang Piperazine compounds used in therapy
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
EP1512683B1 (en) * 1998-03-10 2011-08-31 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
AU4566399A (en) * 1998-06-15 2000-01-05 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6326381B1 (en) * 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU2001238690A1 (en) * 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
MXPA03003868A (es) 2000-10-30 2003-07-28 Janssen Pharmaceutica Nv Inhibidores de tripeptidil peptidasa.
PT1436012T (pt) 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
UA75714C2 (en) 2001-10-22 2006-05-15 Pfizer Prod Inc 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor antagonists and pharmaceutical composition based thereon
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
SI1615646T2 (sl) 2003-04-08 2022-11-30 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije vsebujoče metilnatrekson
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
WO2005058367A2 (en) * 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AU2006220682B2 (en) 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2007005845A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US20090325857A1 (en) * 2006-04-21 2009-12-31 Raphael Beumer Use of opioid receptor antagonists
WO2008064351A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
US7947710B2 (en) 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2009029252A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
TW201118084A (en) * 2009-09-18 2011-06-01 Adolor Corp The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
LT2506712T (lt) 2009-12-04 2019-06-25 Alkermes Pharma Ireland Limited Morfinano dariniai, skirti narkotinių medžiagų perdozavimo gydymui
EP2539706B1 (en) 2010-02-24 2015-03-04 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US9629566B2 (en) 2011-03-11 2017-04-25 Spacelabs Healthcare Llc Methods and systems to determine multi-parameter managed alarm hierarchy during patient monitoring
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2018170465A1 (en) 2017-03-17 2018-09-20 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3759085B1 (en) 2018-02-28 2022-12-14 Dart NeuroScience, LLC Substituted cyclohexyl compounds as nop inhibitors
US20220183586A1 (en) * 2019-03-12 2022-06-16 The Board Of Regents Of The University Of Texas System Simultaneous blood glucose monitoring and gastric emptying scintigraphy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936468A (en) * 1969-10-27 1976-02-03 Sumitomo Chemical Company, Ltd. Phenylbutanol derivatives
AR205452A1 (es) * 1973-12-06 1976-05-07 Endo Lab Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles
US4175197A (en) * 1974-09-06 1979-11-20 Eli Lilly And Company 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
SE7702301L (sv) * 1976-04-08 1977-10-09 Endo Lab Trans-hexahydro-pyrido-indoler
US4115400A (en) * 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
US4284635A (en) * 1978-11-29 1981-08-18 Eli Lilly And Company Analgesic 1,2,4,5-tetra-alkyl-4-arylpiperidines
US4581456A (en) * 1983-09-21 1986-04-08 Eli Lilly And Company Processes for preparing picenadol precursors and novel intermediates thereof
US4663460A (en) * 1983-09-21 1987-05-05 Eli Lilly And Company Intermediates for picenadol
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists

Also Published As

Publication number Publication date
DE69202186T2 (de) 1995-10-05
DE69202186D1 (de) 1995-06-01
EP0506468A1 (en) 1992-09-30
EP0506468B1 (en) 1995-04-26
JP3059292B2 (ja) 2000-07-04
JPH0597807A (ja) 1993-04-20
CA2064382A1 (en) 1992-09-30
CA2064382C (en) 2005-07-05
US5159081A (en) 1992-10-27

Similar Documents

Publication Publication Date Title
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
BR9612334A (pt) Derivados de piperidina 1-(piperidinil 1,2-dissubstituído)-4-substituída como antagonistas do receptor de taquiquinina
ES2106825T3 (es) Derivados de piperidina.
FR2733244B1 (fr) Systeme de stabilisants a base de derives de polyalkylpiperidine
DE69621831D1 (de) Piperazinderivative als tachykinin antagonisten
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
ATE82499T1 (de) Okulare hypotensivagenzien.
DE69619479D1 (de) Azaheterocyclische Tachykinin Rezeptor Antagoniste; NK1 und NK2
DK0729468T3 (da) Ikke-peptid tachykinin-receptor-antagonister
PA8467101A1 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
DE3851081D1 (de) Piperidine als Opioid-Antagoniste.
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
BG99863A (en) Antagonists of fibrogenous receptor
ES2190486T3 (es) 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.
FI932173A0 (fi) 4-(1,2-benzisoxazolyl)piperidinantipsykotiska medel
ATE198202T1 (de) Fibrinogen receptor antagonisten
IT1277329B1 (it) Procedimento per la metilazione del 2,2,6,6-tetrametil-4-piperidone (triacetonammina)
PT736009E (pt) N-oxidos de 4-arilpiperazinas e 4-arilpiperidinas como farmacos antipsicoticos
ES2065668T3 (es) Piperidinas y pirrolidinas disubstituidas como agentes anticolinergicos.
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
ES2189211T3 (es) Derivados de naftotiazolona activos en el receptor dopaminergico d 3.
MX9203166A (es) 1-[(2-fluorofenil) (4-fluorofenil)fenilmetil]-ih-imidazol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506468

Country of ref document: ES